VTP-200 was generally well-tolerated with no product-related serious adverse events (SAEs) Interim data showed encouraging initial immunogenicity results, particularly in relation to the E1, E2 and E6 ...
TEL AVIV, Israel, Aug. 04, 2023 (GLOBE NEWSWIRE) -- ImPact Biotech, the IMmune Photo Activated Cancer Treatment (IMPACT) specialist announces the U.S. Food and Drug Administration cleared ImPact’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results